Join
Live feed
·
PRReleasevia Quantisnow
Xilio Therapeutics Inc. logo

Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting

ByQuantisnow·Wall Street's wire, on your screen.
XLO· Xilio Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track XLO (Xilio Therapeutics Inc.) and more on Quantisnow.